De kinesiske lægemiddelmyndigheder har taget imod salgsansøgningen for Novos vægttabsmedicin Wegovy, der tages gennem munden. Virksomheden konkurrerer i hidsigt tempo på det hurtigt voksende marked, særligt mod Eli Lilly.
Novo Nordisk said on Thursday that China’s drug regulator accepted its application to sell the oral version of its weight-loss drug Wegovy. The Danish drugmaker aims to compete with rival Eli Lilly in the world’s second-largest pharmaceutical market.
Novo Nordisk, Eli Lilly, Pfizer, and local company Innovent Biologics are competing for market share with their versions of once-weekly GLP-1 weight-loss injections in China. The country’s National Health Commission said the rate of overweight or obese people could reach more than 65% by 2030.